全文获取类型
收费全文 | 57704篇 |
免费 | 5665篇 |
国内免费 | 1701篇 |
专业分类
耳鼻咽喉 | 562篇 |
儿科学 | 1260篇 |
妇产科学 | 859篇 |
基础医学 | 7396篇 |
口腔科学 | 1062篇 |
临床医学 | 6494篇 |
内科学 | 10548篇 |
皮肤病学 | 964篇 |
神经病学 | 4723篇 |
特种医学 | 2098篇 |
外国民族医学 | 21篇 |
外科学 | 6980篇 |
综合类 | 5184篇 |
现状与发展 | 7篇 |
一般理论 | 30篇 |
预防医学 | 5005篇 |
眼科学 | 1332篇 |
药学 | 4986篇 |
19篇 | |
中国医学 | 1898篇 |
肿瘤学 | 3642篇 |
出版年
2024年 | 243篇 |
2023年 | 783篇 |
2022年 | 1520篇 |
2021年 | 2279篇 |
2020年 | 1735篇 |
2019年 | 1718篇 |
2018年 | 1802篇 |
2017年 | 1636篇 |
2016年 | 1655篇 |
2015年 | 2011篇 |
2014年 | 2643篇 |
2013年 | 2877篇 |
2012年 | 4269篇 |
2011年 | 4506篇 |
2010年 | 2777篇 |
2009年 | 2259篇 |
2008年 | 3294篇 |
2007年 | 3308篇 |
2006年 | 3182篇 |
2005年 | 2788篇 |
2004年 | 2553篇 |
2003年 | 2393篇 |
2002年 | 2173篇 |
2001年 | 1153篇 |
2000年 | 1013篇 |
1999年 | 816篇 |
1998年 | 476篇 |
1997年 | 417篇 |
1996年 | 374篇 |
1995年 | 331篇 |
1994年 | 284篇 |
1993年 | 196篇 |
1992年 | 374篇 |
1991年 | 349篇 |
1990年 | 333篇 |
1989年 | 278篇 |
1988年 | 271篇 |
1987年 | 298篇 |
1986年 | 308篇 |
1985年 | 285篇 |
1984年 | 230篇 |
1983年 | 178篇 |
1982年 | 129篇 |
1981年 | 126篇 |
1980年 | 121篇 |
1979年 | 238篇 |
1978年 | 160篇 |
1977年 | 138篇 |
1974年 | 128篇 |
1973年 | 138篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
992.
993.
994.
In this study, we established a rat model of optic nerve crush to explore the effects of erythropoietin on retinal ganglion cell axonal regeneration. At 15 days after injury in erythropoietin treated rats, retinal ganglion cell densities in regions corresponding to the 1/6, 3/6 and 5/6 ratios of the retinal radius were significantly increased. In addition, the number of growth associated protein-43 positive axons was significantly increased at different distances (50, 250 and 500 ?m) from the crush site after erythropoietin treatment. Erythropoietin significantly increased growth associated protein-43 protein levels in the retina after crush injury, as determined by western blot and immunofluorescence analysis. These results demonstrate that erythropoietin protects injured retinal ganglion cells and promotes axonal regeneration. 相似文献
995.
996.
ABSTRACT: BACKGROUND: Platinum compounds such as cisplatin and carboplatin are DNA crosslinking agents widely used for cancer chemotherapy. However, the effectiveness of platinum compounds is often tempered by the acquisition of cellular drug resistance. Until now, no pharmacological approach has successfully overcome cisplatin resistance in cancer treatment. Since the Fanconi anemia (FA) pathway is a DNA damage response pathway required for cellular resistance to DNA interstrand crosslinking agents, identification of small molecules that inhibit the FA pathway may reveal classes of chemicals that sensitize cancer cells to cisplatin. RESULTS: Through a cell-based screening assay of over 16,000 chemicals, we identified 26 small molecules that inhibit ionizing radiation and cisplatin-induced FANCD2 foci formation, a marker of FA pathway activity, in multiple human cell lines. Most of these small molecules also compromised ionizing radiation-induced RAD51 foci formation and homologous recombination repair, indicating that they are not selective toward the regulation of FANCD2. These compounds include known inhibitors of the proteasome, cathepsin B, lysosome, CHK1, HSP90, CDK and PKC, and several uncharacterized chemicals including a novel proteasome inhibitor (Chembridge compound 5929407). Isobologram analyses demonstrated that half of the identified molecules sensitized ovarian cancer cells to cisplatin. Among them, 9 demonstrated increased efficiency toward FA pathway-proficient, cisplatin-resistant ovarian cancer cells. Six small molecules, including bortezomib (proteasome inhibitor), CA-074-Me (cathepsin B inhibitor) and 17-AAG (HSP90 inhibitor), synergized with cisplatin specifically in FA-proficient ovarian cancer cells (2008 + FANCF), but not in FA-deficient isogenic cells (2008). In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FAdeficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization. CONCLUSION: Our findings suggest that, despite their lack of specificity, pharmaceutical inhibition of the FA pathway by bortezomib, CA-074-Me, CHK1 inhibitors or HSP90 inhibitors may be a promising strategy to sensitize cisplatin-resistant, FA pathway-proficient tumor cells to cisplatin. In addition, we identified four new small molecules which synergize with cisplatin. Further development of their analogs and evaluation of their combination with cisplatin may lead to the development of efficient cancer treatments. 相似文献
997.
998.
The blood components used in transfusion are a source of exogenous potassium, a critical factor if a patient's potassium intake should be limited. The physician cannot evaluate the total potassium load in a transfusion from plasma values alone; he must also consider red blood cell lysis. The potassium level of stored blood increases with duration of storage, and during the first 24 hours after transfusion, the erythrocytes lyse in vivo, releasing potassium to the extracellular fluid. 相似文献
999.
Multiple electrode aggregometry (MEA) is used to measure platelet function. Pneumatic tube transport systems (PTS) for delivery of patient samples to a central laboratory are often used to reduce turnaround time for vital analyses. We evaluated the effects of PTS transport on platelet function as measured by MEA. 相似文献
1000.